

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**May 18, 2016**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 18, 2016.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Kelly Jones, PharmD

Philip Mubarak, MD

Divya Ahuja, MD

Tan Platt, MD

Edward Behling, MD

Gregory Browning, MD

Cheryl Hartvigsen, R.Ph.

Joni Bollinger, MD

Thomas Phillips, R.Ph.

**SC DHHS Staff:**

Bryan Amick, PharmD, MBA

Jim Bradford, MD

Janet Giles

Constance Holloway, JD

**Magellan Medicaid Admin:**

Lisa Correll, PharmD

Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, May 4, 2016**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

| Company            | Speaker                 | Drug/Class           |
|--------------------|-------------------------|----------------------|
| Alkermes, Inc.     | JD Hammond, PharmD, MPA | Antipsychotics, Inj. |
| Otsuka             | Jason Swartz, RPh, MBA  | Antipsychotics, Inj. |
| Novo Nordisk, Inc. | Joseph Sheehan, MD      | Insulins             |

**C. Drug Classes for Review**

Lisa Correll led the discussion for the following drug classes:

*Classes for Re-Review*

- Antipsychotics, Injectables
- PAH (Pulmonary Arterial Hypertension) Agents, Oral
- NSAIDs, Oral
- Anticoagulants (Subcutaneous)
- Insulins

The chart below represents the recommendations from the P & T Committee:

| ANTIPSYCHOTICS, INJECTABLES   |   |
|---|---|
| Preferred   | Non-Preferred   |
| <b>Abilify Maintena</b> <sup>®</sup><br>Invega Sustenna <sup>®</sup> / Trinza <sup>®</sup><br>Risperdal Consta <sup>®</sup> | Aristada <sup>®</sup><br>Zyprexa <sup>®</sup> Relprevv <sup>™</sup> |

| PAH-Endothelin Receptor Agonists, ORAL                |                      |
|---|----------------------|
| Preferred   | Non-Preferred        |
| Letairis <sup>®</sup><br><b>Tracleer</b> <sup>®</sup> | Opsumit <sup>®</sup> |

| NSAIDs, ORAL  |   |
|---|---|
| Preferred   | Non-Preferred   |
| Diclofenac sodium/SR<br>Ibuprofen<br>Indomethacin<br>Ketorolac<br>Meloxicam<br>Nabumetone | Anaprox<br>Arthrotec<br>Cambia<br>Cataflam<br>Daypro<br>Duexis <sup>®</sup> |

| NSAIDs, ORAL (continued)                         |  |
|--|--|
| Preferred  | Non-Preferred  |
| Naproxen Tab/Suspension<br>Piroxicam<br>Sulindac | Feldene<br>Indocin Susp<br>Mobic<br>Motrin®<br>Naprosyn<br>Nalfon<br>Naprelan®<br>Ponstel<br>Tivorb ex®<br>Vivlodex™<br>Vimovo®<br>Voltaren®<br>Zipsor®<br>Zorvolex®<br>Diclofenac/Misoprostol<br><b>Diclofenac Potassium</b><br><b>Diflunisal</b><br><b>Etodolac</b><br><b>Flurbiprofen</b><br>Fenoprofen<br><b>Indomethacin Cap SR</b><br><b>Ketoprofen</b><br>Mefenamic Acid<br><b>Naproxen Sodium</b><br><b>Oxaprozin</b><br>Tolmetin Sodium Cap |

| ANTICOAGULANTS, SUBCUTANEOUS                  |                             |
|---|-----------------------------|
| Preferred                                     | Non-Preferred               |
| Enoxaparin<br><b>Fondaparinux</b><br>Fragmin® | <b>Arixtra®</b><br>Lovenox® |

| INSULINS   |  |
|--|--|
| Preferred  | Non-Preferred  |
| Humalog 50/50<br>Humalog 75/25<br>Humalog<br>Humulin 70/30<br>Humulin N<br>Humulin R | Afrezza®<br>Apidra®<br>Relion<br><b>Novolin N, R, 70/30</b><br>Toujeo®<br>Tresiba® |

| INSULINS <i>(continued)</i>                   |               |
|---|---------------|
| Preferred                                     | Non-Preferred |
| Lantus<br>Levemir<br>Novolog<br>Novolog 70/30 |               |

5. **Old Business**

None

6. **New Business**

Bryan advised the group that State law requires four meetings per year. Going forward, there will be two meetings in May, one in August and one in November.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

*Classes for Re-Review*

Antipsychotics, Injectables

PAH (Pulmonary Arterial Hypertension) Agents, Oral

NSAIDs, Oral

Anticoagulants (Subcutaneous)

Insulins

8. **Closing Comments**

The next meeting will be held on Wednesday, August 3, 2016, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:40 p.m.